sites. The findings suggest that therapeutic NMDA receptor block in neonates requires higher concentrations of magnesium sulphate in brain tissue. (Arch Dis Child Fetal Neonatal Ed 1998;78:F116-F120) 
Magnesium (Mg

2+
) sulphate has several actions one of which may be to protect the developing brain from the damage to neurons that is caused by the excitotoxic eVects of glutamate, the main excitatory amino acid (EAA) neurotransmitter. Thus magnesium sulphate is proposed for clinical use to combat glutamate excitotoxicity associated with birth asphyxia 1 which causes glutamate to be released with increased concentrations in the extracellular compartment. Mg 2+ may reduce injury by preventing excess glutamate from overactivating the several classes of EAA receptors, especially the N-methyl-D-aspartate (NMDA) receptor.
Epidemiological studies have described how magnesium sulphate administered to pregnant mothers with pre-eclampsia or in preterm labour reduces the incidence of cerebral palsy in low birthweight infants. 2 3 In these clinical conditions Mg 2+ may have several actions, including blocking NMDA receptors.
The NMDA receptor controls a calcium permeable cation channel. 4 Because calcium ion (Ca 2+ ) has a vital role as an intracellular second messenger, NMDA receptors are involved in numerous physiological processes, including coordination of synaptogenesis and synaptic plasticity in the developing brain. 5 Pathologically, overactivation of NMDA receptors may promote calcium mediated excitotoxicity such as follows periods of hypoxiaischaemia and hypoglycaemia, conditions where excess glutamate is released. 6 The NMDA receptor cation channel complex is unique in having several receptor and modulatory sites which recognise individual regulators found in the brain. 7 These modulatory sites include an agonist binding site that binds L-glutamate and L-aspartate, 8 a glycine co-agonist site, 9 10 a voltage-dependent Mg 2+ site, 11 12 a voltage independent inhibitory Zn 2+ site 13 14 and a site which is aVected by the endogenous polyamines spermine and spermidine. 15 The Mg 2+ site is within the cation channel and is occupied at normal membrane potentials which inactivates the NMDA receptor. Depolarisation of neurons, which may be achieved by activation of other glutamate receptors such as the AMPA receptor, is suYcient to overcome the Mg 2+ block and allow ion flow through the cation channel. Another cation channel site recognises phencyclidine (PCP) and other compounds, such as the dissociative anaesthetic ketamine and the anticonvulsant MK-801 (Dizocilpine). PCP-like compounds and MK-801 are noncompetitive antagonists at the PCP site. 16 [18] [19] [20] [21] However, in contrast, NMDA receptors expressed from hippocampal mRNA from 14-15 day old rats were about twofold less sensitive to Mg 2+ than 1 to 2 day old rats. 22 It was also reported that in hippocampal CA3 pyramidal neurons, NMDA channels do not change sensitivity to Mg 2+ induced block during development, whereas the kinetic properties of the NMDA receptor channels seem to alter. 23 
Methods
Brains were removed at necropsy from 17 subjects whose ages ranged from 31 weeks of gestation to 83 years (table 1). Strict inclusion criteria were applied in the use of brain tissue in the study, including death to post mortem examination interval (PMI) of 96 hours or less, death from an acute event without antemortem coma (agonal state), no history of central nervous system disease and no recognisable brain pathology. Post mortem examinations were made by a consultant pathologist whose findings confirmed the absence of brain pathology on both gross and histological examination. Each brain was cut into coronal slices which were rapidly frozen in isopentane at −70°C and stored below −70°C. Similar methods of brain collection and storage do not significantly alter [ 3 H]MK-801 binding in developing and adult brains. 24 Samples of dorsolateral prefrontal cortex (Brodmann area 9) were subdissected from the frozen brain tissue. Extensively washed membranes were prepared with modifications to established procedures. 25 About 100 mg of grey matter was homogenised in 50 volumes of 50 mM TRIS-acetate buVer (pH 7.4) using an Ultra Turrax homogeniser and centrifuged (19 000 × g for 10 minutes at 4°C). The supernatant fluid was discarded and the pellet resuspended in 50 volumes of 50 mM TRIS-acetate (pH 7.4) and centrifuged as before. This washing procedure was repeated with 50 volumes of 5 mM TRIS-acetate (pH 7.4) and three times with deionised water and the pellets stored at −70°C for at least 24 hours. On the day of the assay, pellets were thawed at room temperature and resuspended in 50 volumes of 5 mM TRIS-acetate and centrifuged (19 000 × g, for 10 minutes at 4°C), followed by two further cycles of washing. Binding assays were performed in triplicate in flat bottomed 96-well microplates in a total volume of 200 µl.
Membranes (17-33 µg protein) were incubated in the presence of 5 mM TRIS-acetate (pH 7.4), 4 nM [ 3 H]MK-801 (22 Ci/mmol) for 90 minutes at 25°C. Non-specific binding was defined by 100 µM unlabelled MK-801. Magnesium inhibition curves were performed in the presence of 100 µM glutamate and 10 µM glycine to enhance [
3 H]MK-801 binding. Assays were terminated by vacuum filtration through glass fibre filters (pre-soaked in 0.1% polyethylanimine) using a cell harvester. Wells were washed for 5 seconds with ice cold 5 mM TRIS-acetate (pH 7.4) and filters dispersed in 2 ml of scintillant. Radioactivity was determined after 12 hours using a Packard Tricarb liquid scintillation analyser at 50% counting eYciency. Protein concentrations were measured using a dye method, 26 using bovine serum albumin as standard.
Inhibition of binding was quantified and IC 50 values were calculated using PRISM (GraphPad Software). Statistical analyses were performed using Spearman rank correlation, Student's t test and one way analysis of variance (ANOVA) followed by a Tukey-Kramer multiple comparison post hoc test, using INSTAT (GraphPad Software).
Compounds used and the sources were: MK-801 ([+]-5-methyl-10,11-dihydro-5H-dibenzocyclohepten-5,10-imine maleate) from RBI; [ 3 H]MK-801 from NEN-DuPont; L-glutamate and glycine from Sigma; magnesium sulphate from BDH.
Results
The brains available for the study were subdivided into three groups according to the ages of the subjects (table 1). Two groups had subjects of both sexes whereas the adult subjects were nearly all male. The causes of death, which were many and varied, were typical of subjects of these ages. The only group with a near consistent diagnosis was the infant group (sudden infant death syndrome; SIDS). In our previous work on binding to the NMDA receptor PCP site we have not found that gender influences SIDS. Pathologically, brains from SIDS cases are normal. The post mortem examination interval (PMI) was diVerent for each group and shortest for the adult subjects. A longer PMI for neonates reflects the inevitable necropsy delays. 24 it was not a factor in the present study. Prolonged coma or hypoxia was not involved in the deaths of the infants and neonates, and none of the adult patients was mechanically ventilated.
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Discussion
The main findings reported in this paper are the postnatal increase in the numbers of neocortical NMDA receptors and their response to the co-agonists glutamate and glycine, and the relatively low sensitivity to gest that the expression of several NMDA receptor subunits in the brain varies both regionally and during development. [34] [35] [36] We have explained the age dependent changes in sensitivity to Mg 2+ reported here in terms of developmentally controlled expression of different NMDA subunits, but other possible mechanisms should be considered. Although Mg 2+ sensitivity of NMDA receptors may be modulated in vitro by co-activation of polyamine sites, 18 there is unlikely to be enough endogenous polyamines to explain the pronounced developmental changes in Mg 2+ sensitivity of NMDA receptors. Millimolar concentrations of Mg 2+ may potentiate rather than block NMDA responses, perhaps via polyamine sites. 32 The overall eVects of Mg 2+ on NMDA channel currents may be a balance between reduction via the channel Mg 2+ sites and some potentiation which is dependent on other mechanisms. This balance may alter slightly in the developing brain which expresses immature type NMDA subunits.
We reported earlier that the maximum number of [
3 H]MK-801 binding sites in developing human brain occurred in infancy. 25 There is a widely held opinion that NMDA receptors have trophic functions in the developing brain, and a transient postnatal rise in NMDA receptor numbers 37 may reflect an increased role of the receptor in neural plasticity 5 and also a transient overproduction of glutamatergic synapses. 37 38 In rat brain 36 and probably also in man, there are early postnatal alterations in the proportions of the mRNAs which express the subunits that make functioning NMDA receptors. NMDA receptors in the brain of neonates and young infants may be an immature type of receptor with properties which are more suited to trophic functions than the mature or adult receptor type. The functions and the pharmacological properties of native heteromeric receptors are determined by the proportions of the various co-agonist and modulatory receptor sites which coordinate the opening of cation channels. They in turn are dependent on the subunit composition of the NMDA receptors. The pharmacological properties of NMDA receptors measured in brain preparations may be expected, therefore, to alter during brain development as receptors undergo molecular rearrangements. The present data provide an example of a developmental alteration in NMDA receptor properties in that glutamate and glycine produce a larger increase in [ Mg 2+ sites are an important part of the NMDA receptor complex because they produce the voltage dependent block of NMDA induced ion currents which has been shown in various brain tissue preparations. 11 39 40 Analyses of the properties of the voltage gating of cation channels by Mg 2+ suggest that within the NMDA receptor ion channel complex there are several Mg 2+ sites which are either close to, or just inside, the channel lumen. 41 One Mg 2+ site in cortical neurons occurs almost one third of the distance into the channel pore from the intracellular side. 12 The current interest in magnesium sulphate stems from its potential use as a neuroprotective compound which, by blocking NMDA receptor channels in brain after systemic administration, may be valuable as a treatment given to neonates who have had cerebral hypoxia or perfusion arrest. These are major causes of morbidity and perinatal brain damage which may involve excitotoxic injury caused by glutamate release. In a mouse model of excitotoxic neuronal death magnesium sulphate aVorded protection only after the stage of brain development at which Mg 2+ could block NMDA channels. 43 As we report here and elsewhere, the activity and regulation of NMDA receptors in human brain changes during development and undergo substantial alterations between about 36 weeks of gestation and late infancy. 4 25 A temporary and altered sensitivity of NMDA receptors to Mg 2+ induced blockade in the neonatal brain has obvious practical implications for treatment with magnesium sulphate. Our data show that neonatal cortex has fewer NMDA receptors than older subjects with a below normal response to Mg
2+
. The findings imply that the plasma concentration of magnesium sulphate needed to achieve neuroprotection in neonates will be greater than that in older infants or adults. 
